Celltrion’s Infliximab Biosimilar, becomes Remdantry in Canada
Celltrion, Inc., a leading global biopharmaceutical company, recently announced that its infliximab biosimilar will be marketed in Canada under the new brand name Remdantry starting April 1, 2025, following approval of the product name change by Health Canada. As Remdantry uses the same Drug Identification Number (DIN) as Inflectra, the formulation, indications and dosages of Remdantry […]
